key: cord-1003848-rygfbdmi
authors: Jung, Fang; Liu, Jung‐Sen; Yang, Shih‐Hsing; Tseng, Hui‐Yun; Chou, Shang‐Shing P.; Lin, Jau‐Chen; Jow, Guey‐Mei
title: FJU‐C28 inhibits the endotoxin‐induced pro‐inflammatory cytokines expression via suppressing JNK, p38 MAPK and NF‐κB signaling pathways
date: 2021-10-20
journal: Pharmacol Res Perspect
DOI: 10.1002/prp2.876
sha: a2ec1a62c03e4a909a5bb43586087bcd065d4ccc
doc_id: 1003848
cord_uid: rygfbdmi

Despite marked improvements in supportive care, the mortality rate of acute respiratory distress syndrome due to the excessive inflammatory response caused by direct or indirect lung injury induced by viral or bacterial infection is still high. In this study, we explored the anti‐inflammatory effect of FJU‐C28, a new 2‐pyridone‐based synthetic compound, on lipopolysaccharide (LPS)‐induced inflammation in vitro and in vivo models. FJU‐C28 suppressed the LPS‐induced mRNA and protein expression of iNOS, COX2 and proinflammatory cytokines. The cytokine protein array results showed that LPS stimulation enhanced the secretion of IL‐10, IL‐6, GCSF, Eotaxin, TNFα, IL‐17, IL‐1β, Leptin, sTNF RII, and RANTES. Conversely, the LPS‐induced secretion of RANTES, TIMP1, IL‐6, and IL‐10 was dramatically suppressed by FJU‐C28. FJU‐C28 suppressed the LPS‐induced expression of RANTES, but its parental compound FJU‐C4 was unable to diminish RANTES in cell culture media or cell lysates. FJU‐C28 blocked the secretion of IL‐6 and RANTES in LPS‐activated macrophages by regulating the activation of JNK, p38 mitogen‐activated protein kinase (MAPK) and nuclear factor‐κB (NF‐κB). FJU‐C28 prevented the LPS‐induced decreases in lung function including vital capacity (VC), lung compliance (C chord), forced expiratory volume at 100 ms (FEV100), and forced vital capacity (FVC) in mice with LPS‐induced systemic inflammatory responses. FJU‐C28 also reduced neutrophil infiltration in the interstitium, lung damage and circulating levels of IL‐6 and RANTES in mice with systemic inflammation. In conclusion, these findings suggest that FJU‐C28 possesses anti‐inflammatory activities to prevent endotoxin‐induced lung function decrease and lung damages by down‐regulating proinflammatory cytokines including IL‐6 and RANTES via suppressing the JNK, p38 MAPK and NF‐κB signaling pathways.

Despite marked improvements in supportive care, the mortality rate of acute respiratory distress syndrome (ARDS) due to the excessive inflammatory response caused by viral or bacterial infection-induced direct or indirect lung injury is still high. 1,2 The inflammatory response is an important host defense mechanism that protects against infection and restores damaged tissues to normal physiological states. 3, 4 Macrophages play a crucial role in regulating the innate immune response during inflammatory processes. 5 Lipopolysaccharide (LPS) activates macrophages to release various inflammatory mediators and inflammatory cytokines. 6 However, the prolonged production of inflammatory mediators by macrophages can cause an inflammatory response, eliciting the release of various vascular and cellular danger signals that promote damage to the host and contribute to the pathology of many inflammatory diseases. 7 Therefore, developing effective agents is important for creating new therapeutic approaches for the treatment of inflammatory diseases.

IL-6 is a major proinflammatory mediator that induces the acute-phase response, severe asthma and inflammatory pulmonary diseases. 8-10 IL-6 is a major activator of signal transducer and activator of transcription 3 (STAT3) and blocks apoptosis in cells during the inflammatory process, keeping these cells alive in toxic environments. 11 Several lines of evidence suggest that IL-6 is a pleiotropic cytokine during the transition from innate to acquired immunity to prevent increased tissue damage from the accumulation of neutrophil-secreted proteases and reactive oxygen species during inflammation. 11, 12 Studies have demonstrated that several signaling pathways, including the nuclear factor-κB (NF-κB) and mitogenactivated protein kinase (MAPK) signaling pathways, are upregulated in animal models of acute lung injury (ALI). [13] [14] [15] [16] NF-κB plays a pivotal role in immune and inflammatory responses through the regulation of proinflammatory cytokines, adhesion molecules, chemokines, growth factors and inducible enzymes. 17 Recently, reports have shown that p38 MAPK contributes to LPS-induced IL-6 secretion. 18 Studies have shown that stimulating both the p38 MAPK and NF-κB signaling pathways can induce IL-6 gene expression and release. 19 RANTES (also called CCL5) is a C-C chemokine that plays an important role in recruiting leukocytes, including T lymphocytes, macrophages, eosinophils, and basophils, to inflammatory sites. 20 Several infectious diseases caused by viruses, including dengue viruses, respiratory syncytial virus (RSV) and influenza virus A, cause airway inflammation and significantly induce RANTES secretion and expression in humans and animal models. [21] [22] [23] [24] Recent studies have demonstrated that SARS coronavirus (SARS-CoV) and RSV infection can induce high levels of IL-6 and RANTES (CCL5) in a cell model. 25 High expression of RANTES after primary respiratory syncytial viral infection is associated with the exacerbation of airway disease;

RSV-infected animals treated with anti-RANTES antibodies showed significant decreases in airway hyperreactivity. 26 RANTES expression is associated with CD45-positive inflammatory cell infiltration, which causes pulmonary arterial hypertension. 27 Several animal models of ARDS have shown elevated expression of RANTES induced by either LPS or caerulein, which lead to systemic inflammatory responses and distant lung injury. 28, 29 The treatment of caerulein-induced pancreatitis in mice with Met-RANTES can reduce lung damage. 30 In addition, blocking the RANTES receptor CC-chemokine receptor type 5 may reduce and prevent lung damage in complement component 5a-induced ALI. 31 This evidence suggests that RANTES is involved in various physiopathological processes and may be a target for a new therapeutic strategy by interfering with the binding of this chemokine to its proteoglycan receptor. However, the exact functions of RANTES in pathogen-induced inflammation are still unclear.

2-Pyridones are a class of potent antibacterial agents that are used to treat bacterial infections caused by gram-negative bacteria;

these agents are effective treatments that targets the early release of proinflammatory cytokines and are useful for preventing and/or treating inflammation related to leukocyte infiltration. 32 FJU-C28, which is derived from a 2-pyridone compound, 13 was recently synthesized, and its anti-inflammatory activities and underlying mechanisms remain unknown. In this study, the anti-inflammatory effects of FJU-C28 on the expression of inflammatory mediators were analyzed in vitro, and the efficacy of FJU-C28 in improving lung function in ALI was evaluated by using an in vivo animal model. The profile of cytokines in macrophages with LPS-induced inflammation was identified by using a cytokine protein array, and then the molecular mechanism of the dominant cytokines, including IL-6 and RANTES, in the progression to ARDS was manipulated by using in vitro cell models. containing 10% fetal bovine serum (HyClone), MEM nonessential amino acids (HyClone), 100 mM sodium pyruvate (HyClone), and penicillin/streptomycin (HyClone). The cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air.

The FJU-Cs compound used in this study was synthesized at the 

Cytokine array analysis was performed according to the procedure recommended by the Raybio mouse cytokine antibody array 4 (RayBiotech, Inc.). This cytokine protein array was used to simultaneously determine the relative levels of 40 different cytokines, chemokines, and acute-phase proteins in a single sample. One hundred microliters of cell culture medium was used for each sample. The signal intensity in the membrane of the cytokine protein array was measured by using ImageJ software and is presented as a heat map drawn by using MultiExperiment Viewer (MeV V.4.9.0) software.

RNA was isolated from cells using TRIzol reagent (Invitrogen) as previously described. 32 The concentration of the isolated RNA was measured using an Epoch microplate spectrophotometer (BioTek).

One microgram of RNA was reverse-transcribed to cDNA with random primers and an MMLV RT kit (Epicenter Biotechnologies). The mixture (2 μl) was added to PCR reagents to measure the target mRNA level with specific primers (Table 1) . All real-time PCRs were performed in a volume of 20 μl containing 10 μl of Real-time PCR SYBR Green master mix (Toyobo) using a PikoReal 96 Real-Time PCR System (Thermo Fisher Scientific Inc.), according to our previously described method. 33 The expression of β-actin was used as an internal control for RNA quantification.

RANTES (RayBiotech), IL-1β and IL-6 (eBioscience) concentrations in cell culture media and mouse serum were measured using Enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. The plates were measured at 450 nmol/L using an Epoch microplate spectrophotometer (BioTek Instruments). The concentrations of RANTES, IL-1β and IL-6 in the samples were determined by standard curves.

In brief, cell lysate was separated by 10% SDS-PAGE and trans- 

Ten-week-old male C57BL/6 mice from BioLasco Taiwan Co., Ltd.

were used in the present study. The mice were maintained under standard laboratory conditions as described in a previous study. 34 All animal procedures were approved by the Institutional Animal 

The data for triplicate experiments are expressed as the means and standard errors. All statistical analyses were performed by one-way ANOVA, followed by Tukey's multiple comparison post hoc test. A value of p < .05 was considered to be significant.

To compare the anti-inflammatory effects of the newly synthesized compound FJU-C28 ( Figure 1A ) on LPS-activated murine macrophages to those of the parent compound FJU-C4, 13 RAW264.7 macrophages were pretreated with various concentrations of FJU-Cs for 30 min and then stimulated with or without LPS for 24 h. FJU-C28 protected RAW264.7 macrophages from LPS-induced cell death and exhibited less cytotoxicity than 10 μM FJU-C4 ( Figure 1B ).

LPS stimulation changed the shape of macrophages, resulting in dendritic-like cells with multiple vacuoles in the cytoplasm, whereas the untreated cells were round and small. FJU-C28 dramatically inhibited these changes in morphology in a concentration-dependent manner, and the morphology was similar to that of untreated cells ( Figure 1C ). This effect was consistent with the findings of the cytotoxicity assay. This result indicated that FJU-C28 could suppress the inflammatory response induced by LPS in RAW264.7 macrophages.

In addition, FJU-C28 suppressed the expression of iNOS and COX2 at doses higher than 5 μM ( Figure 1D ). The quantitative immunoblot data are shown in Figure 1E .

The 

To distinguish the effect of various FJU-Cs on LPS-induced inflammation, the cell culture media of RAW264.7 macrophages treated with various conditions were harvested and analyzed by using a mouse cytokine antibody array (left panel of Figure 3 ).

The signal intensities on the array membranes were quantified by densitometry, and the changes in different cytokines are represented as a heat map (right panel of Figure 3 ). The results

showed that several cytokines, including IL-10, IL-6, GCSF, eotaxin, TNFα, IL-17, IL-1β, leptin, sTNF RII, and RANTES, were en- (Table 2 ).

To confirm whether FJU-C28 can suppress the expression of RANTES in RAW264.7 macrophages, the cell culture media and cell lysates of RAW264.7 macrophages treated with various conditions were harvested for ELISA and western blot analysis. The ELISA results showed that the expression of RANTES was enhanced in cell culture media and cell lysates of LPS-treated cells;

FJU-C28 dramatically suppressed the LPS-induced expression of RANTES, but FJU-C4 was unable to reduce the LPS-induced expression of RANTES at 6 h or 24 h ( Figure 4A ). In addition, western blot analysis also confirmed that FJU-C28 dramatically suppressed the LPS-induced protein expression of RANTES at 6 h, but FJU-C4 did not reduce the protein expression of RANTES in treated cells ( Figure 4B ). The secretion of proinflammatory cytokines such as IL-6 and IL-1β in cell culture media was also analyzed by ELISA ( Figure 4C,D) . The results showed that FJU-C28 dramatically reduced the production of RANTES, IL-6 and IL-1β in LPS-treated macrophages. Figure 6D ). In addition, the suppressive effect of SP600125 was better than SB203580 because SP600125 also contributed to the inhibitory effect on the phosphorylation of STAT3 induced by IL-6 stimulation ( Figure S1 ). Interestingly, FJU-C28 can dramatically suppress the IL-6/STAT3 signaling induced by LPS through not only inactivating p38 MAPK and JNK but also reducing the levels of STAT3 protein ( Figure S2 ). The proposed mechanism of action regarding FJU-C28 suppressing the IL-6/STAT3 was illustrated in Figure S3 .

To It is interesting why LPS-induced expression of IL-6 is not completely suppressed by SB203580 or SP600125 even at 10 µM, respectively. We propose that LPS can activate NF-κB, p38 MAPK, and JNK signaling pathways to induce the expression of proinflammatory cytokines such as IL-6. SB203580 or SP600125 alone does not completely suppress the expression of IL-6 because other pathways such as NF-κB may drive the production. Therefore, the part of IL-6 cytokines is secreted to their surrounding environment and then binds to membrane-bound IL-6R to activate IL-6/STAT3 signaling and drive the production of IL-6 via an autocrine. In addition, our data also showed that SP600125 but not SB203580 can suppress the phosphorylation of STAT3 induced by IL-6 stimulation.

Thus, it indicates that the suppressive effect of SP600125 with two hit points on the activation of STAT3 signaling is better than SB203580 with one hit point as shown in Figure 6D . Based on our current data, we propose that acute exposure to LPS can activate NF-κB, p38 MAPK, and JNK signaling pathways to induce the ex- to inhibit various kinase via interacting with hinge binding scaffolds of kinase protein. 52 

These findings suggest that FJU-C28 possesses anti-inflammatory activities to prevent endotoxin-induced lung function decrease and lung damages by down-regulating proinflammatory cytokines including IL-6 and RANTES via suppressing the JNK, p38 MAPK, and NF-κB signaling pathways. These results provide additional insight into the mechanism and new opportunities for therapeutic intervention against lung inflammatory disease.

The 

The authors declare that there is no conflict of interest regarding the publication of this paper.

All procedures on animals were approved by the ethics committee of Fu-Jen Catholic University and performed in accordance with institutional animal care guidelines.

All data generated and analyzed during the study are included in the published article and can be shared upon request.

Jau-Chen Lin https://orcid.org/0000-0002-4358-0602 (B) Cytokines, including RANTES and IL-6, in mouse serum in the control (n = 6), LPS (n = 6) and LPS plus FJU-C28 treatment (n = 6) groups were measured by ELISA.

The quantitative data are expressed as means ± SE. *p < .05 compared with control mice. # p < .05 compared with LPS stimulation alone. LPS, lipopolysaccharide

Complexities of targeting innate immunity to treat infection

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Macrophage activation by endogenous danger signals

Cytokinemediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide

Homeostasis, inflammation, and disease susceptibility

Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts

Role of IL-6 in asthma and other inflammatory pulmonary diseases

Defective inflammatory response in interleukin 6-deficient mice

The proand anti-inflammatory properties of the cytokine interleukin-6

IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation

FJU-C4, a new 2-pyridone compound, attenuates lipopolysaccharide-induced systemic inflammation via p38MAPK and NF-kappaB in mice

Suppression of iNOS and COX-2 expression by flavokawain A via blockade of NF-kappaB and AP-1 activation in RAW 264.7 macrophages

Urinary trypsin inhibitor attenuates lipopolysaccharide-induced acute lung injury by blocking the activation of p38 mitogen-activated protein kinase

Substance P upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-kappaB in a mouse model of burn-induced remote acute lung injury

The nuclear factor NF-kappaB pathway in inflammation

Dual effects of p38 MAPK on TNF-dependent bronchoconstriction and TNF-independent neutrophil recruitment in lipopolysaccharideinduced acute respiratory distress syndrome

p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES

RANTES, macrophageinhibitory protein 1alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children

Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells

Expression of RANTES by normal airway epithelial cells after influenza virus A infection

Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections

RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease

Chemokine RANTES in severe pulmonary arterial hypertension

Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets

Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitisassociated lung injury

Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis

Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin

The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors

Antofine suppresses endotoxin-induced inflammation and metabolic disorder via AMP-activated protein kinase

Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model

Brazilein suppresses inflammation through inactivation of IRAK4-NF-kappaB pathway in LPS-induced Raw264.7 macrophage cells

Inhibitory effects of Angelica sinensis ethyl acetate extract and major compounds on NF-kappaB trans-activation activity and LPS-induced inflammation

Toll-like receptors in the induction of the innate immune response

Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

Fluorofenidone protects mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-1beta release

Effects of 5-ethyl-1-phenyl-2-(1H) pyridone on serum biomarkers of multiorgan dysfunction and mortality in lipopolysaccharide/glactosamine and cecal ligation and puncture models of septic shock in mice

Anti-inflammatory effects of dichloromethane fraction from Orostachys japonicus in RAW 264.7 cells: suppression of NF-kappaB activation and MAPK signaling

ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts

The complexity of NF-kappaB signaling in inflammation and cancer

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

Activators and target genes of Rel/NF-kappaB transcription factors

p38(MAPK): stress responses from molecular mechanisms to therapeutics

Pathological roles of MAPK signaling pathways in human diseases

A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells

Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells

Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis

Cytokine balance in the lungs of patients with acute respiratory distress syndrome

Pyridones in drug discovery: recent advances

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors

GSK3beta-dependent inhibition of AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury

Honokiol protects pulmonary microvascular endothelial barrier against lipopolysaccharideinduced ARDS partially via the Sirt3/AMPK signaling axis

Activation of AMPK enhances neutrophil chemotaxis and bacterial killing

Metformin-stimulated AMPK-alpha1 promotes microvascular repair in acute lung injury

Alcohol consumption promotes colorectal carcinoma metastasis via a CCL5-induced and AMPK-pathway-mediated activation of autophagy

Additional Supporting Information may be found in the online version of the article at the publisher's website. How to cite this article

FJU-C28 inhibits the endotoxin-induced pro-inflammatory cytokines expression via suppressing JNK, p38 MAPK and NF-κB signaling pathways